---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Pharmacodynamics"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Pharmacodynamics. Topics: Brain 5-HT2A receptor occupancy and plasma psilocin; Time course and dose dependence of subjective effects; Onset and resolution of acute effects with COMP360 in healthy participants; Cardiovascular effects: blood pressure, heart rate, and QTc interval with COMP360; 2 further topics. 6 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/pharmacodynamics"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Pharmacodynamics

<a id="heading-2.1.2.6.2"></a>

## 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

### Brain 5-HT2A receptor occupancy and plasma psilocin

> “Psilocybin intake resulted in dose-related 5-HT2AR occupancies up to 72%; plasma psilocin levels and 5-HT2AR occupancy conformed to a single-site binding model.”
> “Subjective intensity was correlated with both 5-HT2AR occupancy and psilocin levels as well as questionnaire scores.”
> “Occmax [95% CI] determined from this model was 76.6 [67.3; 88.0]%, EC50 [95% CI] was 1.95 [1.17; 3.15] μg/L, and R2 was 0.92”
> “Important for clinical studies, psilocin time-concentration curves varied but psilocin levels were closely associated with psychedelic experience.”

Source: [Madsen et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6785028/)

<a id="topic-2.1.2.6.2-2"></a>

### Time course and dose dependence of subjective effects

> “Mean (± SD) durations of subjective effects were 5.6 ± 2.2 hours, 5.5 ± 1.6 hours, and 6.4 ± 2.2 hours”
> “The duration and intensity of subjective effects were dose-dependent.”
> “The plasma concentration-time curve of unconjugated psilocin is consistent with the within-subject effect-time curve as documented with PK-PD modeling in this study.”

Source: [Holze et al. (2023)](https://doi.org/10.1002/cpt.2821)

<a id="topic-2.1.2.6.2-3"></a>

### Onset and resolution of acute effects with COMP360 in healthy participants

> “In total, 511 TEAEs were reported, with a median duration of 1.0 day; 67% of all TEAEs started and resolved on the day of administration.”
> “255 started on the administration day, 235 (92%) of which were resolved that day”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="topic-2.1.2.6.2-4"></a>

### Cardiovascular effects: blood pressure, heart rate, and QTc interval with COMP360

> “Transient elevations in systolic BP, diastolic BP, and HR were seen in most participants, with effects peaking 2 to 3 hours post-dose.”
> “However, there were limitations related to access of data that prevented review of all continuous BP data.”
> “The results from the cardiodynamic evaluation demonstrated that COMP360 has no clinically relevant effect on cardiac conduction but an effect on HR could not be excluded.”
> “The effect on the QTc interval was either small or negative and an effect on ΔΔQTcF exceeding 10 ms can be excluded”

Source: [ISRCTN ISRCTN17905443 basic results (2024)](https://www.isrctn.com/editorial/retrieveFile/65a8139b-10a3-4341-b7e1-d15edeb0ab8e/45481)

> “There were no clinically significant findings in vital signs.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

> “Physiologically, psilocybin is known to cause mild increases in blood pressure and heart rate”

Source: [Sarparast et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9177763/)

<a id="topic-2.1.2.6.2-5"></a>

### Cognitive function and emotional processing after a single dose of COMP360

> “There were no clinically relevant between-group differences in CANTAB global composite score, CANTAB cognitive domain scores, or emotional processing scale scores.”
> “These results indicate that 10 mg and 25 mg doses of psilocybin were generally well tolerated when given to up to six participants simultaneously and did not have any detrimental short- or long-term effects on cognitive functioning or emotional processing.”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="topic-2.1.2.6.2-6"></a>

### Preclinical and in vitro pharmacology of psilocin metabolites

> “Neither 4-HIAA nor 4-HTP showed relevant interactions at assessed 5-HT receptors.”
> “The major metabolite 4-HIAA and 4-HTP were inactive at human 5-HT receptors but the activity of oxidized psilocin metabolites and norpsilocin remain to be assessed.”

Source: [Thomann et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11089204/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
